Back to Search
Start Over
A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer
- Source :
- Cancer. 118:5008-5014
- Publication Year :
- 2012
- Publisher :
- Wiley, 2012.
-
Abstract
- BACKGROUND: For patients with stage III through IVB head and neck squamous cell carcinoma (HNSCC), concurrent high-dose cisplatin plus radiation therapy is a widely accepted standard of care. HNSCC tumors that express high levels of vascular endothelial growth factor have been associated with a worse prognosis, and bevacizumab may sensitize tumors to cisplatin and radiation. METHODS: Planned treatment consisted of definitive intensity-modulated radiation therapy (IMRT) (total, 70 grays) with concurrent cisplatin (50 mg/m2 on days 1, 2, 22, 23, 43, and 44) and bevacizumab (15 mg/kg on days 1, 22, and 43). The primary endpoint was 2-year progression-free survival (PFS), and overall survival (OS) was a secondary endpoint. RESULTS: Forty-two previously untreated patients (34 men and 8 women; median age, 55 years; range, 27-75 years) with stage III through IV HNSCC without distant metastasis (oropharyngeal carcinoma, 39 patients; laryngeal carcinoma, 3 patients) were treated. Human papillomavirus (HPV) status by was determined by in situ hybridization (HPV positive, 16 patients; HPV negative, 14 patients, unknown HPV status, 12 patients). The toxicities (determined according to version 3.0 of Common Terminology Criteria for Adverse Events Common) that were experienced by all patients (any grade) were mucositis, lymphopenia, leukopenia, throat pain, fatigue, and anemia. There were 2 treatment-related deaths, including 1 sudden death and 1 death from aspiration pneumonia. The median follow-up was approximately 31.8 months (range
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
Bevacizumab
Performance status
business.industry
medicine.medical_treatment
Cancer
Common Terminology Criteria for Adverse Events
medicine.disease
Head and neck squamous-cell carcinoma
Sudden death
Radiation therapy
Internal medicine
medicine
Carcinoma
business
medicine.drug
Subjects
Details
- ISSN :
- 0008543X
- Volume :
- 118
- Database :
- OpenAIRE
- Journal :
- Cancer
- Accession number :
- edsair.doi...........8ea3cb8e88c26769a9b6bbbab1bc41de